Skip to Main Content

Loc3CAR: B7-H3-Specific CAR T-Cell Therapy for Children with Primary CNS Tumors

About this study

New treatments are needed to help children and young adults whose brain cancers return or are hard to treat. CAR T–cell therapy is a type of immunotherapy where the body’s T cells are changed in the lab so that they can attack cancer cells. Loc3CAR is a study that uses CAR T cells to treat children and young adults with brain tumors that have returned or are hard to treat. The changed T cells (Loc3CAR) recognize a protein called B7-H3, found in many childhood brain tumors.

In this study, we will collect white blood cells (T cells) from the patient. We will change those cells in the lab to make the Loc3CAR cells. The Loc3CAR cells are returned to the patient so they can attack the tumors with a specific type of protein called B7-H3. The Loc3CAR cells are given using a small, flexible tube (catheter) that enters the brain and delivers the cells. An IV is not used.

Eligibility overview

To take part in this study, you must:

  • Have a tumor that is positive for B7-H3
  • Be 21 years old or younger
  • Patients must stay in Memphis while getting CAR T-cells.

The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.


Full title:

Locoregional Delivery of B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cells for Pediatric Patients with Primary CNS Tumors

Study goal:

The purpose of this study is to find: 1) the largest dose of Loc3CAR T cells that is safe to give patients with B7-H3–positive brain tumors; 2) the side effects of Loc3CAR T cells; 3) the effect Loc3CAR T cells have on brain tumors. This trial will help scientists better understand how the immune system fights this kind of tumor. What we learn from this study could help us create better treatments.


Brain tumorsDIPG, DMG


Up to 21 years old

Clinical trials categories:

Childhood Cancer Diffuse Intrinsic Pontine Glioma (DIPG)

Diffuse Midline Glioma

Brain Tumors

For physicians and researchers

Patients accepted to St. Jude must be referred by a physician or other qualified medical professional. Learn how St. Jude can partner with you to care for your patient.


Learn more